Plaque Psoriasis

Risankizumab was well tolerated during a phase 3 study that found the drug had better efficacy than placebo at 16 weeks and treatment withdrawal at 2 years in patients with moderate to severe plaque psoriasis, according to a study published in JAMA Dermatology.

The FDA has approved a supplemental biologics license application for ixekizumab in pediatric patients with moderate to severe plaque psoriasis, according to a press release from Eli Lilly.

Several novel treatments for moderate to severe plaque psoriasis were associated with the highest Psoriasis Area and Severity Index response rates, according to a comprehensive assessment of efficacy published in JAMA Dermatology.

Taltz was found to be more effective at improving signs and symptoms among patients with moderate to severe plaque psoriasis than Tremfya, according to a multicenter, randomized, double-blind, parallel-group, phase 4 study.

The investigational IL-17A and IL-17F inhibitor bimekizumab was superior to adalimumab in achieving a 90% improvement in Psoriasis Area and Severity Index score after 16 weeks, according to a press release from UCB.

ATLANTA — Age at onset of psoriasis determines whether psoriasis or psoriatic arthritis starts first in patients with psoriatic arthritis, according to data from the PsART-international web-based registry presented here.

As students go back to school and parents resign beach gear to its out-of-season digs at the back of the garage, Healio Dermatology reflects on big news from August on acne treatment, private equity in the marketplace and much more.

Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

Older adults are more likely to be poorly represented in randomized controlled trials of systemic treatment for plaque psoriasis, according to findings published in the Journal of the American Academy of Dermatology.

Private equity-based dermatology practice consolidation increased at a mean rate of 65% each year from 2012 to 2017, according to researchers from Brigham and Women’s Hospital and Harvard Medical School, in the current top story from August.